Keywords
IL-6, IL-10, lactoferrin, growth failure
This article is included in the Agriculture, Food and Nutrition gateway.
This article is included in the Global Public Health gateway.
This article is included in the All trials matter collection.
IL-6, IL-10, lactoferrin, growth failure
Growth failure is still an important health problem, with weight-for-age (WAZ) and length-for-age (LAZ) declining during the golden period or golden 1,000 days (period during pregnancy until second years of life),1 and insignificant growth thereafter.2 Nutritional intervention during this period will impact a child’s growth, development and ability to thrive.1 Infection in children causes growth failure by provoking a systemic immune response which affects the nutritional status,3 especially as a result of a reduction of insulin-like growth factor 1 (IGF-1).4
Undernutrition refers to children who are underweight, stunted or wasted, or have nutrient deficiency which makes the children vulnerable to infection.5 The induction of the acute phase response and proinflammatory cytokine production caused by infection directly affect bone remodeling which is important for long bone growth,3 and also inhibits chondrogenesis.6 Pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6 and tumor necrosis factor-alpha (TNF-α) were found to have increased in stunted children, which also increases leptin levels leading to a limited appetite.4 These proinflammatory cytokines also cause bone breakdown.6 IL-6 has anti- and pro-inflammatory functions. After it binds with IL-6 receptors in the liver, it stimulates hepatocytes to produce acute-phase proteins and cytokines via multiple signaling pathways.7
Oral nutritional supplements (ONS), also known as food for special medical purposes, contain both macro- and micronutrients that are sufficient to meet daily nutritional needs for those at risk of malnutrition.8 ONS is prescribed to increase nutritional intake due to insufficiency in diets to meet daily nutritional requirements,9 particularly protein and calories.10 ONS not only provides some benefits for hospital admission patients such as a reduced length of hospital stay (LOS), reduced inpatient cost, complication rates, readmission rates and improved lean body mass recovery,11 but also improves energy intake and nutritional status such as body weight, length and mid-arm circumference.12 For children, ONS is a dairy milk-based product, which is designed to provide an energy density of 1–1.5 kcal/ml, and it is expected to be effective in improving growth.13
Lactoferrin (Lf) concentration within the whey protein that is contained in the modified cow’s milk formula is only 0.1 mg/ml.14 ONS contains 10.8 g of protein per 100 g, which is 46% whey and 54% casein. The effect of Lf supplementation (dose 0.6 g/L and 1.00) compared to standard infant formula on body weight showed no significant difference in children until 12 months old.15 Lf acts as an innate immune regulator and defense due to its antimicrobial properties.16 It can interact with the immune system, such as influencing cytokine activity by upregulating anti-inflammatory cytokines (IL-4 and IL-10) or modulating proinflammatory cytokines.17 An in vitro study showed that Lf (10 mg/mouse i.v.) before thymectomy reduced IL-6 by 70%, and TNF-α by 30% 4 hours after an operation.18 A study in adults showed that Lf reduced systemic inflammatory biomarkers by 61%, improved immune function by 75%, changed immune cell activity by 40% and reduced respiratory tract infection outcomes by 60%. In adults, lactoferrin has been shown to reduce IL-6 by 24.9 pg/mL.19
Here we investigate the effect of lactoferrin in ONS towards IL-6 and IL-10 in failure to thrive children with infection for 90 days of intervention.
The study passed ethical exemption and was declared to be ethically appropriate by the Health Research Ethics Committee, Airlangga University, Surabaya, Indonesia, number 226/EC/KEPK/FKUA/2021 on October 4th 2021 and registered on ClinicalTrials.gov number ID: NCT05289674, initial released on May 3rd, 2022.
A quasi experimental pre- and post- study design was performed from October 2021 until July 2022 recruiting children aged between 1 years (12-months-old) and 5 years (60-months-old) with failure to thrive due to infectious illness (mainly urinary tract infection and tuberculosis (TB)) diagnosed by a paediatrician (the researcher) based on clinical and laboratory findings at Husada Utama Hospital outpatient unit, Surabaya, Indonesia. The subjects included in the study were excluded if they had fluid retention, organomegaly, a tumor mass, congenital abnormalities, cerebral palsy or hormonal disorders and syndromes. A written informed consent was signed by the parents as approval to participate in the study after the researcher explained the importance, the risks and the benefits of this study.
The sample size was determined using the formula below:
Note:
N = sample size
Zα = standard deviation (α) 5% (1.96)
Zβ = power, the researchers determined 90% (0.842)
P1 = clinical judgement 15% = 0.1
P2 = standard effect P2 = 25.5% = 0.25.20
P = ½ (P1+P2) = 0.175
Q = 1-P = 0.825
Q1 = 1-P1 = 0.9
Q2 = 1-P2 = 0.75
The sample size was 80 subjects; pre- and post-design needed for the study was 160 samples.
The subjects were given an oral nutritional supplement or ONS with Lf (1 ml ~1 kcal, 400 ml/day), SGM Eksplor Gain Optigrow® prescribed by the researchers for 15 days consumption (equal to 4 boxes of 400 g) for initial intervention to detect any adverse reaction. The authors used this formula due to its relatively cheaper cost compared to other high calorie formula (ONS) available in Indonesia. The parents also had dietary counseling, animal protein was provided and a medication plan was given according to the underlying disease. Parents were asked to report any side effects to the researcher’s team by phone for further medical treatment. The parents were asked to visit the doctor after 14 days of ONS consumption for anthropometric measurements, compliance and side effect monitoring at day 15. While visiting, parents also received ONS for the next 15 days consumption (day 16 to 30), and were asked to visit the doctor again on day30, 60 and 90. At the 30-day visit, parents received ONS for two months’ consumption (day 31 to day 60, and day 61 until day 90) (8 boxes of 400 g) and anthropometric measurements.
Blood was withdrawn via vena cubiti by a laboratory employee at Husada Utama Hospital to measure IL-6 (human IL-6 ELISA kit, code E0090Hu, BT Lab) and IL-10 (human IL-10 ELISA kit, code E0102Hu, BT Lab) before (day 0, when the parents agreed to participate in this study) and after the intervention (day 90). After the blood samples were collected, they were placed in a non-EDTA containing tube for micro-centrifugation to separate blood plasma from blood serum at 3000 rpm for 10 minutes. The supernatant was removed and placed in a PCR tube of 1.5 mL, then kept in a freezer at -4oC.
An indirect sandwich ELISA was performed to analyse IL-6 and IL-10 levels before- and after nutritional intervention using blood serum. For the sandwich ELISA, all reagents (standard solution, wash buffer, substrate solution A, substrate solution B and stop solution) were brought to room temperature before use (27oC).21
Preparation of standard solution
A total of 120 μL standard solution (640 ng/ml) was diluted with 12 μL standard diluent to produce a 320 ng/L standard stock solution, and it was then allowed to rest for 15 minutes. Standard duplication points were made using a serial dilution of standard stock solution to produce 160 ng/L, 80 ng/L, 40 ng/L and 20 ng/L solutions.
Preparation for wash buffer solution
Then 20 ml of wash buffer concentrate 25 × was added to distilled water to yield 500 mL of 1 × wash buffer. The wash buffer was mixed gently if crystals formed in the concentrate until the crystals had completely dissolved.
Assay procedure
The assay procedure was performed at room temperature after we determined the number of strips required for the assay, and then we inserted the strips in the frames for use.
1. 50 μL of the standard solution was added into all the sample wells.
2. Then 50 μL standard solution was added into the standard wells.
3. 40 μL of sample was added to the sample wells and then 10 μL of human IL-6 or IL-10 antibody was added. Then 50 μl streptavidin-HRP was added to sample wells and standard wells, but not the blank control well. Each of them were mixed before the wells were placed on the plate and then sealed for incubation at 37oC for 60 minutes.
4. After 60 minutes of incubation, the seals were removed, and the plates were washed 5 times with wash buffer; the wells were soaked in 300 μl of wash buffer for 30 seconds to 1 minute for each wash.
5. 50 μl of substrate solution A and 50 μl of substrate solution B were added to each well and the plate was covered and incubated for 10 minutes at 37oC in the dark.
6. 50 μl of stop solution was added to each well, so that the blue colour changed to yellow immediately.
We then determined the optical density (OD value) of each well immediately using a microplate reader set at 450 nm of wavelength within 30 minutes after the stop solution was added, and then the standard curve was made.21
Body weight was measured using a Seca 354 digital baby scale or a Seca 813 electronic flat scale) and body length/height was measured using a Seca 415 infantometer or Seca 213 stadiometer). Both measurements were taken twice by a trained nurse in the outpatient department of Husada Utama Hospital. The weight and length/height were the average value of the two measurements. When the subjects were weighed and measured, they wore light clothes without footwear or hair accessories. Anthropometry measurement for weight-for-age z-score (WAZ), length-for-age or height-for-age z-score or height-for-age z-score (LAZ/HAZ) and weight-for-length or weight-for-height z-score or weight-for-height z-score (WLZ/WHZ) were determined using WHO Anthro offline version 3.2.2. All the data are summarized in the underlying data22 and extended data.23
Statistical analysis conducted in this study was a test of normality and homogeneity, independent sample T-test or Mann-Whitney U test, Fischer exact test, Pearson chi-square, paired sample T-test or Wilcoxon, two-way ANOVA and one-way ANOVA using IBM SPSS Statistics version 21.
Seventy-five subjects were involved in the study and divided into two groups based on the age of the participant: group-1 (age 1–2 years, n = 39) and group-2 (age 2–5 years old, n = 36), as summarized in Figure 1.
Table 1 summarizes the characteristics of the subjects who participated in the study. The ratio of male/female was 12/13 and there was no significant difference in gender distribution in both groups (p = 0.108). There was no significant difference in the main complaint (p = 0.229), duration of complaints (p = 0.580), WAZ (p = 0.482) and WLZ/WHZ (p = 0.499). Age, ideal body weight and height age were lower in group-1 compared to group-2 (p < 0.05). LAZ was lower in group-1 compared to group-2 (-1.95 ± 1.17 vs. -1.19 ± 0.86, p = 0.002).
Subject’s characteristics | Group-1 (mean ± SD) | Group-2 (mean ± SD) | p |
---|---|---|---|
Age, months | 16.74 ± 3.63 | 35.44 ± 7.70 | 0.0001 |
Gender, n (%) | 0.1082 | ||
- Male | 15 (36.59) | 21 (58.33) | |
- Female | 24 (58.53) | 15 (41.67) | |
Main complains: | 0.2293 | ||
- Feeding difficulties with stagnant body weight gain | 10 (25.64) | 16 (44.44) | |
- Stagnant body weight gain and length gain | 1 (2.56) | 0 | |
- Body weight gain | 27 (69.29) | 20 (55.56) | |
- Fever with liquid pups | 1 (2.56) | 0 | |
Duration of complaint, months | 7.84 ± 4.29 | 12.23 ± 11.15 | 0.5801 |
WAZ | -1.52 ± 1.08 | -1.35 ± 0.99 | 0.4824 |
WAZ categories, n (%) | 0.8743 | ||
- Weight faltering (normo-weight) | 25 (64.10) | 21 (58.33) | |
- Underweight | 12 (30.77) | 13 (36.11) | |
- Severely underweight | 2 (5.13) | 2 (5.56) | |
LAZ/HAZ | -1.95 ± 1.17 | -1.19 ± 0.86 | 0.0024 |
LAZ/HAZ categories, n (%) | 0.0043 | ||
- Normo-stature | 17 (43.59) | 29 (80.56) | |
- Stunted | 14 (35.90) | 5 (13.89) | |
8 (20.51) | 2 (5.56) | ||
- Severely stunted | |||
WLZ/WHZ | -0.85 ± 0.92 | -1.01 ± 1.12 | 0.4994 |
WLZ/WHZ categories, n (%) | 0.4863 | ||
- Good nutrition | 35 (89.74) | 29 (80.56) | |
- Wasted | 3 (7.69) | 6 (16.67) | |
- Severely wasted | 1 (2.56) | 1 (2.78) |
The incidence of underweight and severely underweight children in group-1 and group-2 were 33.33% and 5.33% respectively, and there was no significant difference in WAZ categories in both groups (p = 0.874). While stunted and severely stunted children in group-1 and group-2 were 25.33% and 13.33% respectively, with a higher incidence of stunted/severely stunted children in group-1 compared to group-2 (56.41% vs. 19.45%, p = 0.004). However, the incidence of stunted/severely stunted children in group-1 was predominantly boys (6 boys vs. 1 girl). The incidence of wasted and severely wasted children in group-1 and group-2 were 12% and 2.67% (p = 0.486).
The effect of ONS on body weight and body length/height change is summarized in Table 2. Initial body weight before treatment was lower in group-1 compared to group-2 (p = 0.000). post intervention body weight was lower in group-1 than in those of group-2 (p = 0.000) but the weight change (Δ body weight) in both groups showed no significant difference (922.56 ± 671.28 vs. 855.55 ± 577.16 g, p > 0.05). The initial body length/height was shorter in group-1 compared to group-2 (p = 0.000), so the late body length/height was shorter in group-1 compared to group-2 (p = 0.000). Body length/height change was greater in group-1 compared to group-2 (3.49 ± 1.43 vs. 2.08 ± 1.04 cm, p = 0.000).
Parameters | Group-1 (mean ± SD) | Group-2 (mean ± SD) | p |
---|---|---|---|
Initial body weight | 8,735.38 ± 1,318.64 | 12,164.17 ± 1,688.89 | 0.0001 |
Late body weight | 9,657.95 ± 1,607.48 | 13,019.72 ± 1,768.91 | 0.0001 |
Body weight change (Δ Body weight) | 922.56 ± 671.28 | 855.55 ± 577.16 | 0.6461 |
Initial body length/height | 75.14 ± 5.26 | 91.39 ± 4.80 | 0.0001 |
Late body length/height | 78.63 ± 5.02 | 93.47 ± 4.84 | 0.0001 |
Body length/height change (Δ length/height) | 3.49 ± 1.43 | 2.08 ± 1.04 | 0.0001 |
IL-6 and IL-10 levels during the intervention are summarized in Table 3. The levels of IL-6 post-intervention (day 90) were not significantly different from pre-intervention (128.45 ± 109.92 vs. 111.76 ± 78.10 pg/mL, p = 0.554), although there was a decline (-16.68 ± 91.09 pg/mL) in both groups (-13.42 ± 97.80 vs. -20.23 ± 84.46 pg/mL, p = 0.749). There was no significant difference in IL-6 levels before the treatment in both groups (p < 0.232) and after treatment (p < 0.191). IL-10 level was significantly reduced after the intervention (461.20 ± 392.12 became 261.28 ± 163.97 pg/mL, Δ = 199.92 ± 339.01 pg/mL, p = 0.000). The reduction in IL-10 showed no significant difference in either group (-183.24 ± 378.50 vs. -217.99 ± 294.61 pg/mL, p = 0.518).
IL-6 markers | Group-1 (mean ± SD) | Group-2 (mean ± SD) | p |
---|---|---|---|
Initial levels of IL-6 | 113.80 ± 109.24 | 144.31 ± 109.96 | 0.2321 |
Initial levels of IL-6 based on nutritional status | 0.6692 | ||
- Weight faltering | 94.12 ± 85.49 | 126.13 ± 93.17 | |
- Undernutrition | 136.76 ± 130.54 | 191.58 ± 139.54 | |
Late levels of IL-6 | 100.38 ± 73.95 | 124.09 ± 81.59 | 0.1911 |
Late levels of IL-6 based on nutritional status | 0.1212 | ||
- Weight faltering | 95.31 ± 70.06 | 115.52 ± 76.85 | |
- Undernutrition | 108.51 ± 81.65 | 166.89 ± 98.51 | |
Δ IL-6 | -13.42 ± 97.80 | -20.23 ± 84.46 | 0.7491 |
Δ IL-6 levels based on nutritional status | 0.0012 | ||
- Weight faltering | -9.00 ± 83.72 | -19.86 ± 64.76 | |
- Undernutrition | -18.56 ± 114.38 | -21.18 ± 126.85 | |
Initial levels of IL-10 | 423.66 ± 385.66 | 501.88 ± 400.43 | 0.3921 |
Initial levels of IL-10 based on nutritional status | 0.1312 | ||
- Weight faltering | 407.09 ± 367.31 | 411.74 ± 318.22 | |
- Undernutrition | 442.99 ± 415.93 | 736.23 ± 507.72 | |
Late levels of IL-10 | 240.41 ± 165.75 | 283.89 ± 161.27 | 0.2541 |
Late levels of IL-10 based on nutritional status | 0.6502 | ||
- Weight faltering | 211.15 ± 100.40 | 256.25 ± 137.08 | |
- Undernutrition | 274.56 ± 217.39 | 355.76 ± 202.48 | |
Δ IL-10 | -183.24 ± 378.50 | -217.99 ± 294.61 | 0.6611 |
Δ IL-10 levels based on nutritional status | 0.1132 | ||
- Weight faltering | -195.94 ± 345.44 | -155.49 ± 234.96 | |
- Undernutrition) | -168.43 ± 423.58 | -380.47 ± 378.91 | |
Initial value of IL-6/IL-10 ratio | 0.33 ± 0.28 | 0.33 ± 0.14 | 0.9911 |
Initial value of IL-6/IL-10 ratio based on nutritional status | 0.1792 | ||
- Weight faltering | 0.28 ± 0.17 | 0.34 ± 0.16 | |
- Undernutrition | 0.38 ± 0.37 | 0.29 ± 0.16 | |
Late value of IL-6/IL-10 ratio | 0.43 ± 0.12 | 0.45 ± 0.12 | 0.6161 |
Late value of IL-6/IL-10 ratio based on nutritional status | 0.5602 | ||
- Weight faltering | 0.43 ± 0.12 | 0.44 ± 0.11 | |
- Undernutrition | 0.44 ± 0.11 | 0.47 ± 0.12 | |
Δ IL-6/IL-10 ratio | 0.12 ± 0.29 | 0.12 ± 0.17 | 0.2621 |
Δ IL-6/IL-10 ratio based on nutritional status | 0.1252 | ||
- Weight faltering | 0.15 ± 0.19 | 1.00 ± 0.16 | |
- Undernutrition | 0.06 ± 0.37 | 0.18 ± 0.21 |
There was significantly improvement in the IL-6/IL-10 ratio after the intervention (0.33 ± 0.22 vs. 0.44 ± 0.12, Δ = 0.11 ± 0.23, p = 0.000). The reduction in the IL-6/IL-10 ratio showed no significant difference in either group (0.11 ± 0.29 vs. 0.12 ± 0.17, p = 0.991).
The levels of IL-6 based on anthropometric categories are summarized in Table 4. Based on the LAZ categories, there was a significant difference in IL-6 levels pre-intervention (p = 0.045), in which the stunted group had higher levels of IL-6 compared to those with a normal stature (212.06 ± 146.05 vs. 115.81 ± 93.84 pg/mL, p = 0.037). Although there was no significant difference, IL-6 was higher in the stunted group compared to those who were severely stunted (212.06 ± 146.05 vs. 85.45 ± 89.06 cm, p = 0.057). There was no significant difference in post-intervention levels of IL-6 (p = 0.083); however, IL-6 was lower in normal stature children compared to stunted and severely stunted children. Although IL-6 levels were higher in the stunted group compared to the severely stunted group, there was no significant difference between both groups (212.06 ± 146.05 vs. 85.45 ± 89.06 pg/mL, p = 0.057). Changes in IL-6 (ΔIL-6) based on the LAZ/HAZ categories showed no significant difference (p = 0.055), but the changes in severely stunted children were higher compared to the stunted group (47.33 ± 93.48 vs. -41.66 ± 108.69 pg/mL, p = 0.036) and the normal stature group (47.33 ± 93.48 vs. -20.28 ± 77.36 pg/mL, p = 0.031). This was due to increased IL-6 in severely stunted children, but reduced IL-6 in stunted children and those of normal stature.
Markers | Pre-intervention (mean ± SD) | Post-intervention (mean ± SD) | ΔIL-6 (mean ± SD) |
---|---|---|---|
IL-6 based on LAZ/HAZ categories | |||
- Normo-stature | 115.81 ± 93.84 | 104.81 ± 48.67 | -20.28 ± 77.36 |
- Stunted | 212.06 ± 146.05 | 117.51 ± 115.94 | -41.66 ± 108.69 |
- Severely stunted | 85.45 ± 89.06 | 132.78 ± 103.03 | 47.33 ± 93.48 |
p value | 0.0452 | 0.0831 | 0.0552 |
IL-6 based on WAZ categories | |||
- Normo-weight | 125.59 ± 99.41 | 109.49 ± 75.87 | -16.09 ± 73.95 |
- Underweight | 145.73 ± 151.51 | 101.54 ± 73.55 | -44.19 ± 137.03 |
- severely underweight | 103.70 ± 85.38 | 181.84 ± 111.85 | 78.14 ± 32.06 |
p value | 0.9032 | 0.1731 | 0.0142 |
IL-6 based on WLZ/WHZ categories | |||
- Good nutritional status | 131.54 ± 110.91 | 109.49 ± 75.98 | -22.05 ± 92.83 |
- Wasted | 129.02 ± 110.60 | 138.75 ± 97.46 | 9.73 ± 84.73 |
- Severely wasted | 26.83 ± 5.26 | 63.04 ± 8.72 | 36.22 ± 3.46 |
p value | 0.2352 | 0.3911 | 0.1482 |
The levels of IL-6 based on the WAZ categories showed no significant difference pre-intervention (p = 0.903) or post-intervention (p = 0.173), but the change in IL-6 (ΔIL-6) showed a significant difference (p = 0.014), where the WAZ in severely underweight children increased, while the underweight and weight faltering decreased. Therefore, severely underweight children had higher changes of IL-6 compared to stunted children (78.14 ± 32.06 vs. -44.19 ± 137.03 pg/mL, p = 0.012) and weight faltering/normal weight children (78.14 ± 32.06 vs. -16.09 ± 73.95 pg/mL, p = 0.001).
The initial and late changes of IL-6 (ΔIL-6) based on WLZ/WHZ categories showed no significant difference (p > 0.05). The initial level of IL-6 was higher in good nutritional status subjects compared to wasted and severely wasted. But after the intervention, IL-6 levels in good nutritional status subjects were reduced (-22.05 ± 92.83 pg/ml), while the wasted and severely wasted group increased (9.73 ± 84.73 and 36.22 ± 3.46 pg/ml respectively).
Initial and late levels of IL-10, and changes of IL-10 based on the anthropometric categories are summarized in Table 5. There was no significant difference in IL-10 before and after the intervention, or in changes of IL-10 (p < 0.05) based on the LAZ/HAZ categories. A similar phenomenon was also seen in the WAZ and WLZ/WHZ categories (p < 0.05).
Markers | Pre-intervention | Post-intervention | ΔIL-10 |
---|---|---|---|
IL-10 based on LAZ/HAZ categories | |||
- Normo-stature (n = 52) | 420.51 ± 350.98 | 242.98 ± 133.22 | -177.53 ± 292.88 |
- Stunted (n = 13) | 666.72 ± 451.21 | 302.92 ± 213.36 | -363.80 ± 413.83 |
- Severely stunted (n = 10) | 405.61 ± 469.84 | 302.30 ± 213.36 | -103.31 ± 422.42 |
p value | 0.1141 | 0.5351 | 0.0762 |
IL-10 based on WAZ categories | |||
- Weight faltering (normo-weight (n = 56) | 437.99 ± 351.68 | 253.73 ± 148.63 | -184.25 ± 297.31 |
- Underweight (n = 15) | 497.15 ± 477.20 | 260.51 ± 216.90 | -236.64 ± 440.80 |
- severely underweight (n = 4) | 651.36 ± 630.80 | 369.88 ± 147.97 | -281.48 ± 536.04 |
p value | 0.5381 | 0.3971 | 0.9562 |
IL-10 based on WLZ/WHZ categories | |||
- Good nutritional status (n = 64) | 457.82 ± 370.84 | 257.03 ± 159.36 | -200.79 ± 331.63 |
- Wasted (n = 9) | 571.20 ± 536.68 | 320.00 ± 201.23 | -251.19 ± 421.01 |
- Severely wasted (n = 2) | 74.55 ± 40.29 | 133.16 ± 25.89 | 58.61 ± 14.41 |
p value | 0.2681 | 0.3021 | 0.1562 |
The IL-6/IL-10 ratio based on anthropometric measurements is summarized in Table 6. The IL-6/IL-10 ratio based on the LAZ/HAZ categories showed no significant difference pre- and post-intervention. However, ONS supplementation increased the IL-6/IL-10 ratio in all LAZ/HAZ categories. In the WAZ categories, severely underweight children had a lower IL-6/IL-10 ratio compared to underweight children, even though there was no significant difference. The IL-6/IL-10 ratio increased after ONS therapy in all WAZ categories. A higher increment was seen in the severely underweight, but there was no significant difference. The WLZ/WHZ categories also showed no significant difference in the initial and late changes of the IL-6/IL-10 ratio.
Markers | Pre-intervention | Post-intervention | ΔIL-10 |
---|---|---|---|
IL-6/IL-10 based on LAZ/HAZ categories | |||
- Normo-stature (n = 52) | 0.32 ± 0.16 | 0.43 ± 0.11 | 0.12 ± 0.02 |
- Stunted (n = 13) | 0.39 ± 0.38 | 0.45 ± 0.13 | 0.07 ± 0.41 |
- Severely stunted (n = 10) | 0.30 ± 0.27 | 0.46 ± 0.11 | 0.15 ± 0.27 |
p value | 0.3902 | 0.7641 | 0.6981 |
IL-6/IL-10 based on WAZ categories | |||
- Weight faltering (normo-weight (n = 56) | 0.34 ± 0.24 | 0.44 ± 0.16 | 0.10 ± 0.26 |
- Underweight (n = 15) | 0.30 ± 0.16 | 0.43 ± 0.11 | 0.12 ± 0.13 |
- severely underweight (n = 4) | 0.19 ± 0.04 | 0.47 ± 0.16 | 0.28 ± 0.18 |
p value | 0.1412 | 0.8091 | 0.3401 |
IL-6/IL-10 based on WLZ/WHZ categories | |||
- Good nutritional status (n = 64) | 0.33 ± 0.23 | 0.44 ± 0.11 | 0.11 ± 0.25 |
- Wasted (n = 9) | 0.28 ± 0.14 | 0.45 ± 0.12 | 0.17 ± 0.18 |
- Severely wasted (n = 2) | 0.44 ± 0.31 | 0.49 ± 0.16 | 0.05 ± 0.15 |
p value | 0.6752 | 0.8041 | 0.7391 |
The prevalence of stunted and severely stunted children under two-years-old was 33.7%24 and 45.4% in Nigerian children,25 which was higher compared to this study. While the prevalence in two- to five-year-old children in Gaza was 19.6%,26 The prevalence of stunted/severely stunted children was higher in group-1 compared to group-2 in our study, which was similar to the study conducted in Nigeria, accounting for 45.5% vs. 12.2%.25 However, a study in West Sulawesi, Indonesia found that children aged two to five years had a higher incidence of stunted/severely stunted growth compared to children aged one- to two-years-old, 33.64 vs. 23.12%.27
Stunted growth was found to be associated with age, and it was more prevalent in children aged less than 24-months-old.28 Due to the incidence of stunted growth, which was higher in group-1, the LAZ value was significantly lower in group-1 compared to group-2. It was also found that children with stunted growth were significantly shorter in length/height than the control group in another study.29 It was reported that children aged 12–23 months old had an increased risk of stunting by 1.8 times.24,30
In group-2, the incidence of stunted/severely stunted growth was predominant in males, which is in line with Akombi et al. (2017), in which male (sex) was one of the stunting risk factors in 0–5-year-olds.25 This is in line with this study, suggesting that males are more vulnerable to health inequalities.31 The biological reason is due to the sex difference in the immune and endocrine systems, and testosterone, luteinizing hormone and follicle stimulating hormone are suspected to play a role.32 Feeding practice preferences between boys and girls such as early weaning in boys, and boys tend to consume greater than one meal of complementary feed during 24-hours may also play a part.33
ONS intervention in undernourished or at nutritional risk children aged nine months to 12-years-old improved body weight by 0.423 kg after six months of intervention and height gain was 0.417 cm compared to the control, with greater gains in weight in the first 7–10 days of intervention (0.089 kg).34 ONS improved growth in underweight children aged five- to 12-years-old after six and 12 months,35 which was in line with this study, where both group-1 and group-2 gained weight. Formula feeding supplemented with lactoferrin is safe for infants under one year old with no difference in growth rate (g/day).15
Lactoferrin intervention in children with diarrhoea aged 12–36 months old increased the LAZ/HAZ score (p = 0.03) compared to the placebo,36 and the children also showed an increment in length/height. A similar result was also found in Vietnamese children aged 24–48 months old in a 12-month intervention. The intervention of 450 kcal of additional ONS during the first three months resulted in an increase in height of 1.62 cm,37 which was lower than our results in a similar group (group-2). A higher calorie density intervention (2.4 kcal/ml vs. 1.5 kcal/ml) for 28 days increased the children’s height by 0.87 [0.59–1.16] and 0.55 [0.17–0.93] cm, p = 0.007 in children aged greater than one year and less than 12 years old with growth faltering.13
Lactoferrin is known to have a bacteriostatic or bactericidal effect and can activate the immune response of an organism, act accordingly and limits tissue damage.38 It can therefore reduce the incidence of acute gastrointestinal symptoms and reduce the duration of respiratory symptoms in children under 12 months old due to viral or bacterial infection.39 Regarding the immunological profile, when comparing an infant who received Lf supplementation vs. non-Lf supplementation vs. standard infant formula, although there was no significant difference between groups, there was an increase in TGF-β1 (6.5 vs. 4.3 vs. 2.8 ng/mL), TGF-β2 (0.26 vs. 0.26 vs. 0.22 ng/mL) and IL-2 (0.21 vs. 0.5 vs. 0.4 pg/mL), but a decrease in TNF-α (-2.4 vs. -1.5 vs. -1.7 pg/mL) during a four month intervention.40 A study that examined piglets with a 2 ml/day supplementation showed a decrease in bacterial colonies compared to those without Lf supplementation (1.109 × 107 vs. 3.6183 × 108 CFU) via an anal swab after a seven-day intervention.41 It was stated that Lf induced the development of T cell helper type 1 (Th1) immunity, so created the balance of monocytic pro- and anti-inflammatory cytokines. In a dose-dependent manner, Lf enhanced pro-inflammatory response in vitro (splenocyte and adherent (F4/80+) splenocyte populations, bone marrow derived monocytes (BMM), and J774A.1 cultured cells) and induced IL-12 and IL-10 production and increased the ratio IL-12:IL-10 in lipopolysaccharide (LPS) stimulated cells.42 A study of Mycobacterium tuberculosis infection treated with Bacillus Calmette–Guérin (BCG) and Lf emulsified with Freund’s adjuvant in mice showed a decreased mycobacterial load in the lungs and spleen. It also increased the protection against M. tuberculosis,16,43,44 via downregulation of proinflammatory mediators (TNF-α, IL-1β) by modulation of macrophages and dendritic cell ability to present antigens and stimulate T-cells. Lf also increased IFNγ, which was the specific response towards Th1.16 A study examining mice with urinary tract infection due to Escherichia coli showed that Lf intervention orally was able to decrease the number of bacteria in the kidneys and bladder after 24 h of Lf consumption, and reduced IL-6 by urinary leucocytes.45 A study conducted on Senegalese children receiving tetanus vaccine in stunted children aged one- to nine-years-old showed that the production of IFNγ was compromised.2 It was stated that undernutrition is related to immunodeficiency even when it is mild, whether the innate or adaptive immune systems.2
In our study, even though there was no significant difference in IL-6 levels before and after the intervention, Lf reduced IL-6, which is in line with other studies showing a reduction in undernutrition groups. It was found that IL-6 levels were lower in undernutrition compared to good nutrition groups (2.54 pg/mL vs. 6.02 pg/mL, p < 0.0001).46 Genetic investigation showed that the IL-6 164 gene with a GG and GC genotype (mutant phenotype) was more frequent in undernourished children.47
When the groups were examined based on the LAZ/HAZ categories, stunted subjects had higher IL-6 levels compared to normal stature and there was a significant difference compared to severely stunted. This is in line with a study in Egyptian children, where IL-6 was higher in stunted compared to normal stature children (1.6 ± 0.2 vs. 1.5 ± 0.3 pg/mL),48 but it was decreased in malnourished compared to normal children.46 This showed that when the children had an LAZ/HAZ score greater than or equal to -2 SD, IL-6 was increased but it decreased when children had an LAZ/HAZ score greater or equal to -3 SD. On malnutrition, the acute-phase response was attenuated, and the production of cytokines decreased. An animal study showed that IL-1β production decreased in malnourished guinea pigs induced with endotoxins.7 Stunting is a form of growth failure due to long term nutritional deficiency or it is caused by chronic malnutrition or recurrent undernutrition.49,50 After a six-month intervention with food supplementation, stunted Bangladeshi children aged 12–18 months old experienced an IL-6 increment (from 0 [0–1.2] to 1.68 [0.83–4.7] pg/mL, p = 0.001),51 which contradicts this study as IL-6 levels were reduced in stunted and normal stature children. However, IL-6 was found to have increased in severely stunted children, so the post-intervention levels of IL-6 were higher in severely stunted even though there was no significant difference. Severely stunted children might undergo these immune alterations which are similar to severely acute malnutrition, so IL-6 levels were lowest at the outset but increased drastically after the intervention to surpass normal stature and stunted children. It was stated that immune function is an activity with high costs on energy demand, and in developing children the allocation of energy in immune functions may lead to a trade-off with physical growth, particularly those with exposure to infection.52
A similar anomaly was also seen in the WAZ categories even though there was no significant difference. Being underweight has been used as an indicator of undernutrition due to a short-term nutritional deficiency.49 However, an in vitro study using peripheral blood mononuclear cells (PBMC) taken from children suffering from protein energy malnutrition (PEM) contradicted this study, which showed an increment in IL-6 expression after stimulation with LPS,53 even though it was expressed earlier, reached its peak earlier, and lasted longer than controls in rats.54 As the immune function is costly in terms of energy, it has negative effects on growth. In children with mildly elevated immune activity, they experience a growth reduction of up to 49%,52 as seen in underweight children who experienced an increase in IL-6 due to the trade-off in body fat between immune function and growth.52
Regarding malnutrition, lymphatic tissue, particularly the thymus, experiences atrophy, leads to a reduction in delayed-type hypersensitivity responses, followed by a reduction in levels of antibodies in severely malnourished children (≥-3 SD of WLZ/WHZ WHO child growth standards), but it remains intact in moderate malnutrition (leucocyte and lymphocyte, high levels of immunoglobulin, particularly IgA, and acute phase response), and cytokine patterns are skewed towards a Th2-response.55 However, our study found that IL-6 started to reduce in wasted patients, with the lowest levels in those that were severely wasted. Nutritional intervention increases IL-6 in both wasted and severely wasted, but it is reduced with good nutrition, which is in line with research that states undernutrition, even in the mildest form causes immunodeficiency.56
Wenling C57BL/6 J mice in a wasting model’s study, which underwent 14 days of weight loss, showed increases of IL-10 in the malnourished group at three and at 14 days.57 It was stated that malnutrition modifies the body’s resistance against infection, particularly the immune response. Lipopolysaccharide (LPS) injection (1.25 μg i.v.) in a protein-energy malnutrition (PEM) mouse model, showed that the circulating levels of IL-10 were increased, and high levels were found in bone marrow cells, which showed immunodeficiency.58 This finding was in-line with a study in children with marasmic-PEM, IL-10 was significantly higher compared to controls (19.08 ± 5.93 vs 10.46 ± 3.90 pg/mL; p = 0.000).59 This may be caused by the deficits of NF-kB activation. NF-kB was the major transcription pathway for proinflammatory cytokine production.60 Using BMI as the parameter to determine malnutrition, subjects with severe malnutrition (BMI <16.5) had higher levels of IL-10 (8.0 ± 3.6 pg/mL) compared to those with moderate malnutrition (BMI = 16.5-18.4) (2.6 ± 4.3 pg/mL) and good nutrition (BMI >18.5) (2.8 ± 0.7 pg/mL) in adults,61 which was similar to the WAZ category where IL-10 was slightly increased in those underweight, and increased drastically in those severely underweight.
Nutritional intervention increases IL-10 significantly in children aged 12–60 months old with moderate and severe malnutrition receiving curd (milk product) compared to leaf protein concentrate (LPC) (from 30.9 ± 29.5 to 67.4 ± 96.2 pg/mL vs. 29.2 ± 25.8 to 31.5 ± 24.9 pg/mL). Based on Gomez criteria for malnutrition severity, children with mild malnutrition had lower IL-10 compared to children with severe malnutrition. It was higher in subjects aged more than two years old compared to two- to five-year-olds due to a balancing pro-inflammatory response to minimalize tissue damage.62 In malnourished children, IL-10 was found to be reduced, while in line with this study, IL-10 was depressed in severely wasted subjects.63 However, the level of IL-10 was still normal in severely stunted or severely underweight children. The reduction is due to a deficiency in the number and functional Th cells, which may be caused by incomplete differentiation of T lymphocyte precursors and steroid-induced lympholysis.63 Another study of malnourished children due to inadequate food intake (anorexia nervosa) and diarrhoea receiving nutritional intervention in the form of milk and yogurt, showed increased IFNγ production post intervention,64 which is in-line with this study on severely wasted subjects. However, in undernutrition subjects and weight faltering subjects, IL-10 tends to reduce, and a higher reduction was seen in undernutrition subjects, which showed that before intervention undernutrition subjects may experience immune alterations, as seen in the IL-6/IL-10 ratio, which was higher in undernutrition group-1, but lower in group-2. At post intervention, almost all the group had a similar value, ranging from 0.43 to 0.47. Adipose tissue is the main storage for nutrients, which can sense that nutrients are inadequate by releasing adipokines (particularly leptin) to control cellular metabolism and immune function. So, undernutrition has a direct impact on adipose tissue (volume and number), and directly influences the immune system. Leptin not only mediates glucose and lipid metabolism but also immune function, by stimulating activation, proliferation and production of pro-inflammatory cytokine (IL-6, TNF-α, monocytes, macrophages, dendritic cells, and NK cells). Leptin also promotes T-cell activation and development towards Th-1 and Th-17 cell subset which is proinflammatory. Regarding undernutrition, there was leptin depletion and in contrast adiponectin is produced, resulting in the polarization towards M2 or an alternative macrophage which then secrets IL-10 and IL-1Rα. This limits the activation of the NF-kB pathway, and reduces both T-cells or B-cells. Moreover, cortisol hormone restrains the generation of the proinflammatory immune response, so the ability of macrophages and neutrophils to infiltrate the infection site was also restrained. Proinflammatory cytokine production is also reduced, but anti-inflammatory cytokines (IL-10 and IL-33) are increased.5
IL-6 has been used as a potential biomarker to identify patients receiving anti-inflammatory therapies as it is secreted widely as a response to pathological states such as infection, inflammation and cancer. IL-10 acts as an anti-inflammatory response, it is secreted as the response to dampen pro-inflammatory bursts and minimize tissue damage. The balance of IL-6 and IL-10 is an important biomarker reflecting the homeostasis of the immune response. In Covid-19 patients, each point increment of the IL-6/IL-10 ratio was associated with a 5.6 times more severe outcome.5 In children with pneumonia, the IL-6/IL-10 ratio at 9.61 determines those with severe pneumonia to those with mild disease (sensitivity 76.5% and specificity 93%).65
Lactoferrin in ONS intervention improved immune response homeostasis by balancing IL-6 and IL-10 and improved the IL-6/IL-10 ratio, not only body weight but also body length.
Written informed consent for publication of the patients’ details was obtained from the parents of the patients.
Figshare: Underlying data for ‘Effect of Lactoferrin in Oral Nutrition Supplement (ONS) towards IL-6 and IL-10 in Failure to Thrive Children with Infection’, https://www.doi.org/10.6084/m9.figshare.21813975. 22
This project contains the following underlying data:
• Data file: Table 1: Data for Manuscript Effect of Lactoferrin in Oral Nutrition Supplement (ONS) towards IL-6 and IL-10 in Failure to Thrive Childre.xlsx
• Data archive 1: Elisa IL-6 Pre Intervention.rar
• Data archive 2: Elisa IL-6 Post Intervention.rar
• Data archive 3: Elisa_IL-10 Pre Intervention.rar
• Data archive 4: Elisa_IL-10 Post Intervention.rar
Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).
Figshare: Extended data for ‘Effect of Lactoferrin in Oral Nutrition Supplement (ONS) towards IL-6 and IL-10 in Failure to Thrive Children with Infection’, https://www.doi.org/10.6084/m9.figshare.22210798.v2. 23
This project contains the following extended data:
• Informed consent: Essential information for potential research participants (WHO-CIOMS 2016)
• Airlangga University: Ethical clearance
• ClinicalTrials.gov: Protocol registration
• ClinicalTrials.gov: Completed study
• Study protocol
Figshare: TREND checklist for ‘Effect of Lactoferrin in Oral Nutrition Supplement (ONS) towards IL-6 and IL-10 in Failure to Thrive Children with Infection’, https://www.doi.org/10.6084/m9.figshare.22210798.v2. 23
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0)
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
No
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Our combined areas of expertise involve human milk, maternal-infant health, biomarkers of stress (e.g., cortisol) and immunity/immune responses (e.g., cytokines, antibodies), anthropometry, human skeletal growth and plasticity, and biological specimen collection (including blood draws, saliva and milk collections), as well as enzyme immunoassay estimations.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Assessment of children, Differently abled and elderly
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 3 (revision) 19 Dec 23 |
read | read |
Version 2 (revision) 20 Oct 23 |
read | read |
Version 1 28 Jul 23 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)